BR112015022907A2 - formas de sal de (2-(2-(4-fluorfenil)tiazol-4-il) propan-2-il) carbamato de (s)-quinuclidin-3-ila - Google Patents

formas de sal de (2-(2-(4-fluorfenil)tiazol-4-il) propan-2-il) carbamato de (s)-quinuclidin-3-ila

Info

Publication number
BR112015022907A2
BR112015022907A2 BR112015022907A BR112015022907A BR112015022907A2 BR 112015022907 A2 BR112015022907 A2 BR 112015022907A2 BR 112015022907 A BR112015022907 A BR 112015022907A BR 112015022907 A BR112015022907 A BR 112015022907A BR 112015022907 A2 BR112015022907 A2 BR 112015022907A2
Authority
BR
Brazil
Prior art keywords
quinuclidin
thiazol
propan
fluorophenyl
salt forms
Prior art date
Application number
BR112015022907A
Other languages
English (en)
Other versions
BR112015022907B1 (pt
BR112015022907A8 (pt
Inventor
Siegel Craig
Zhao Jin
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50543351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015022907(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR112015022907A2 publication Critical patent/BR112015022907A2/pt
Publication of BR112015022907A8 publication Critical patent/BR112015022907A8/pt
Publication of BR112015022907B1 publication Critical patent/BR112015022907B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups

Abstract

resumo patente de invenção: "formas de sal de (2-(2-(4-fluorfenil) tiazol-4-il) propan-2-il) carbamato de (s)- quinuclidin-3-ila". a presente invenção refere-se a formas de sal de (2-(2-(4-fluorfenil)tiazol-4-il)propan-2-il)carbamato de (s)-quinuclidin-3-ila úteis como um inibidor de glicosilceramida sintase (gcs) e para o tratamento de doenças metabólicas, tais como doenças de armazenamento lisossomal, ou sozinhas ou em combinação com terapia de substituição de enzima, e para o tratamento de câncer.
BR112015022907-7A 2013-03-15 2014-03-14 Formas cristalinas de sal de (2-(2-(4-fluorfenil) tiazol-4-il) propan-2-il) carbamato de (s)- quinuclidin-3-ila e seus usos BR112015022907B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791706P 2013-03-15 2013-03-15
US61/791,706 2013-03-15
PCT/US2014/027081 WO2014152215A1 (en) 2013-03-15 2014-03-14 SALT FORMS OF (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate

Publications (3)

Publication Number Publication Date
BR112015022907A2 true BR112015022907A2 (pt) 2017-07-18
BR112015022907A8 BR112015022907A8 (pt) 2019-11-26
BR112015022907B1 BR112015022907B1 (pt) 2022-07-12

Family

ID=50543351

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022907-7A BR112015022907B1 (pt) 2013-03-15 2014-03-14 Formas cristalinas de sal de (2-(2-(4-fluorfenil) tiazol-4-il) propan-2-il) carbamato de (s)- quinuclidin-3-ila e seus usos

Country Status (34)

Country Link
US (1) US9518049B2 (pt)
EP (1) EP2970250B1 (pt)
JP (1) JP6438455B2 (pt)
KR (1) KR102302064B1 (pt)
CN (1) CN105189490A (pt)
AR (1) AR095435A1 (pt)
AU (1) AU2014240028B2 (pt)
BR (1) BR112015022907B1 (pt)
CA (1) CA2906691A1 (pt)
CL (1) CL2015002701A1 (pt)
DK (1) DK2970250T3 (pt)
EA (1) EA037527B1 (pt)
ES (1) ES2872326T3 (pt)
HK (1) HK1214821A1 (pt)
HR (1) HRP20210692T1 (pt)
HU (1) HUE054349T2 (pt)
IL (1) IL241229B (pt)
JO (1) JO3713B1 (pt)
LT (1) LT2970250T (pt)
MA (1) MA38488A1 (pt)
MX (1) MX370178B (pt)
MY (1) MY181766A (pt)
PH (1) PH12015502021A1 (pt)
PL (1) PL2970250T3 (pt)
PT (1) PT2970250T (pt)
RS (1) RS61852B1 (pt)
SA (1) SA515361078B1 (pt)
SG (1) SG11201507054YA (pt)
SI (1) SI2970250T1 (pt)
TN (1) TN2015000427A1 (pt)
TW (1) TWI713438B (pt)
UY (1) UY35439A (pt)
WO (1) WO2014152215A1 (pt)
ZA (1) ZA201506602B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117679415A (zh) * 2013-12-11 2024-03-12 建新公司 葡糖神经酰胺合酶抑制剂
US10519157B2 (en) * 2018-02-09 2019-12-31 X-Cutag Therapeutics, Inc. Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof
CN114040762A (zh) 2019-02-04 2022-02-11 建新公司 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病
CA3166777A1 (en) * 2020-02-03 2021-08-12 Nigel Patrick Somerville CRAWFORD Methods for treating neurological symptoms associated with lysosomal storage diseases
AU2021311131A1 (en) 2020-07-24 2023-03-23 Genzyme Corporation Pharmaceutical compositions comprising venglustat
MX2023001285A (es) 2020-07-30 2023-02-22 Genzyme Corp Metodos para reducir la concentracion de glicoesfingolipidos en el tejido cerebral y metodos de tratamiento de enfermedades neurodegenerativas que implican los mismos.
WO2022215083A1 (en) * 2021-04-05 2022-10-13 Msn Laboratories Private Limited, R&D Center Solid state forms of (s)-quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl) carbamate or salts and process for its preparation thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
CA2305768A1 (en) 1997-10-29 2000-02-24 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
CA2586761A1 (en) 2004-11-10 2006-05-18 Genzyme Corporation Methods of treating diabetes mellitus
WO2010091104A1 (en) 2009-02-06 2010-08-12 Exelixis, Inc. Glucosylceramide synthase inhibitors
MX356873B (es) 2009-08-28 2018-06-18 Sinai School Medicine Uso farmacéutico de una esfingomielinasa ácida (asm) con aumento escalonada de la dosis para tratar la deficiencia de esfingomielinasa ácida.
BR112013023774B1 (pt) * 2011-03-18 2022-01-11 Genzyme Corporation Inibidores de glicosilceramida sintase

Also Published As

Publication number Publication date
EA201591706A1 (ru) 2016-02-29
IL241229A0 (en) 2015-11-30
UY35439A (es) 2014-10-31
HRP20210692T1 (hr) 2021-06-11
ZA201506602B (en) 2023-04-26
JP6438455B2 (ja) 2018-12-12
EA037527B1 (ru) 2021-04-08
ES2872326T3 (es) 2021-11-02
NZ712659A (en) 2020-11-27
BR112015022907B1 (pt) 2022-07-12
CL2015002701A1 (es) 2016-03-18
EP2970250A1 (en) 2016-01-20
EP2970250B1 (en) 2021-04-21
US9518049B2 (en) 2016-12-13
HUE054349T2 (hu) 2021-09-28
MX370178B (es) 2019-12-04
RS61852B1 (sr) 2021-06-30
PL2970250T3 (pl) 2021-12-06
AU2014240028A1 (en) 2015-10-15
WO2014152215A1 (en) 2014-09-25
PT2970250T (pt) 2021-05-07
CN105189490A (zh) 2015-12-23
DK2970250T3 (da) 2021-07-12
LT2970250T (lt) 2021-05-10
JP2016513679A (ja) 2016-05-16
KR20150132333A (ko) 2015-11-25
AU2014240028B2 (en) 2018-08-02
IL241229B (en) 2019-12-31
HK1214821A1 (zh) 2016-08-05
TW201502127A (zh) 2015-01-16
SA515361078B1 (ar) 2018-06-14
BR112015022907A8 (pt) 2019-11-26
MX2015012295A (es) 2016-05-16
JO3713B1 (ar) 2021-01-31
AR095435A1 (es) 2015-10-14
KR102302064B1 (ko) 2021-09-13
US20160039805A1 (en) 2016-02-11
MA38488A1 (fr) 2017-10-31
MY181766A (en) 2021-01-06
PH12015502021A1 (en) 2016-01-11
SG11201507054YA (en) 2015-10-29
TN2015000427A1 (en) 2017-01-03
SI2970250T1 (sl) 2021-06-30
TWI713438B (zh) 2020-12-21
CA2906691A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
BR112015005227A2 (pt) inibidores de glicosilceramida sintase
BR112015022907A2 (pt) formas de sal de (2-(2-(4-fluorfenil)tiazol-4-il) propan-2-il) carbamato de (s)-quinuclidin-3-ila
BR112013023774A2 (pt) inibidores de glicosilceramida sintase
CL2013003638A1 (es) Compuestos inhibidores de metaloenzimas; composición que comprende dichos compuestos; uso de la composición para tratar o prevenir una enfermedad asociada a metaloenzimas en plantas; uso para inhibir metaloenzimas en microorganismos y tratar un trastorno fúngico en plantas.
EA201890641A2 (ru) СТИМУЛЯТОРЫ sGC
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
BR112014029301A2 (pt) métodos de tratamento de síndrome metabólica através de modulação da proteína choque térmico (hsp) 90-beta
SG10201804952QA (en) Glucosylceramide synthase inhibitors
BR112015020667A2 (pt) método de preparar inibidores de glucosilceramida sintase
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
WO2014165713A3 (en) Treatment of inflammatory conditions by modulation of hyaluronan and hyaluronidase activity
BR112018067967A2 (pt) tratamento de pacientes com hipercolesterolemia familiar homozigótica por meio de terapia hipolipemiante
BR112012028409A2 (pt) método para produzir pleurodese em um sujeito mamífero e kit.
MX2017000184A (es) Agentes de interaccion enzimatica.
WO2014036105A3 (en) Inhibitors of memapsin 2 cleavage for the treatment of alzheimer's disease
TN2013000368A1 (en) Glucosylceramide synthase inhibitors
CL2015000442A1 (es) Compuestos derivados de acilguanidinas espirociclicas, inhibidores de la actividad de la enzima beta-secretasa (bace1); compuestos intermediarios; composicion farmaceutica; y uso para tratar un trastorno o enfermedad seleccionado de alzheimer, trisomia 21 (sindrome de down), demencia senil, parkinson y glaucoma, entre otros.
EA201991189A1 (ru) СТИМУЛЯТОРЫ sGC
TH170238A (th) รูปเกลือของ (s)-ควินิวคลิดิน-3-อิล (2-(2-(4-ฟลูออโรฟีนิล)ไทอาโซล-4-อิล)โพรเพน-2-อิล)คาร์บาเมต
TH153719A (th) สารยับยั้งของกลูโคซิลเซรามีดซินเทส

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2014, OBSERVADAS AS CONDICOES LEGAIS